New YORK CITY

October 25, 2018

MEDIA KIT 2018

/ 4 PRIX GALIEN USA FOUNDING COMMITTEE

/ 5 2018 AWARDS COMMITTEE

/ 6-7 GALIEN FORUM Overview & Background “They participated in the Forum”

/ 8-9 TESTIMONIALS FROM AROUND THE GLOBE

/ 10 HALL OF FAME - HISTORY OF THE PRIZE AND MEDAL

/ 11 PRIX GALIEN USA

/ 12 THE PRO BONO HUMANUM AWARD

/ 13 WHO WAS GALEN

/ 14 PRIX GALIEN MEDSTART UP

/ 15 PRIX GALIEN USA WINNERS

Pre-event & On-siteResources for Journalists

Galien Foundation events are conducted fully on the record, and we welcome

and invite members of the media to participate as engaged stakeholders via

onsite discussion, as well as via social media, and to report on proceedings

and outcomes.

We certainly appreciate coverage of our events, but our priority is to help you

explore and uncover today’s key issues and connect with the people and diverse

organizations we bring together that make the world a healthier place.

To help facilitate your engagement with our speakers and stakeholders,

we are delighted to work with you in the lead-up to our 2018 Forum and

Ceremony on:

Arranging interviews with key speakers

and stakeholders

Reserving private spaces for on-site interviews

Sharing our latest programs and speaker lists

Providing hi-resolutions imagery (including photos

of people, spaces, logos, etc.)

For more information and register for a press pass please contact:

Finn PartnersHolmes Report & PR News Midsize Agency of the Year

Contact:Giana GreggaT +1 312 329 3910M +1 708 703 2210 giana.gregga@finnpartners.com

Helpful linkswww.galienfoundation.org

Prix Galien USA

Forum (latest programs, participants,

registration, and reports)

Pro Bono Humanum Award

Med StartUp Award

Prix Galien Around the Globe

Prix Galien Hall of Fame

2

Sue Desmond-Hellmann, Ethiopia Clinic site visit

The Prix Galien is more than an award: it is a movement with a mandate to foster, recognize and reward excellence in scientific innovation to improve the state of human health. Building on an unrivaled network of Top biomedical scientists including Nobel Laureates in medicine, the Prix Galien manages an independent, cross-functional and geographically diverse program of events and sponsorships to brand “the best of the best” in new medicines and diagnostics.

Our scope is global, and our commitment to progress in medicine is both measurable and concrete. Our members express this through the establishment of productive relationships to build lasting bridges between the commercial research enterprise and local communities engaged in public policy, science, finance, academic research and the media.

In addition to recognizing advances in promising therapies, the Prix Galien’s annual Pro Bono Humanum Award for humanitarian achievements brings a unique focus to the intersection between science, business

and politics. The outcome we seek is guided by the synthesis principle that underpins the conduct of science itself: successful innovation where financing, physical assets, knowledge and skills are combined from many sources to move new ideas quickly “from the bench to the bedside,” on behalf of patients everywhere.

A truly global program present in 14 countries*

Our program includes a review of contributions from a new generation of innovators representing diverse sectors in health. Our theme: better cross-cultural contacts, harmonized regulation, internal business process improvements, new information technologies and effective public-private partnerships can remove barriers to the commercialization of good medicines and expand access to these benefits to all who need them.

2018

Through our partnership with the Élie Wiesel Foundation for Humanity and our first initiative in Africa, 2018 will represent a new and exciting stage in the evolution of the Prix Galien as the pre-eminent “force populaire” behind the global scientific enterprise. With the support of our sponsoring organizations, our efforts will extend to all who see medical innovation not only as an industrial policy asset but as a source of social progress – where private enterprise and public engagement combine to deliver a greater public good.

We invite all communities with a commitment to the conduct and promotion of life sciences innovation to contribute to this important work.

* Belgium, Canada, China, France, Germany, Greece, Italy, Netherlands, Poland, Russia, Spain, Switzerland, United Kingdom and the United States.

Mission

3

The Prix Galien Award recognizes

outstanding achievements in improving

the global human condition through the

development of innovative drugs and

other treatments.

The Prix Galien was created in 1970 in

honor of Galen, the father of medical

science and modern pharmacology.

Worldwide the Prix Galien is regarded

as the equivalent of the Nobel Prize in

biopharmaceutical research.

innovation to improve

the human condition

4

2007-2011Committee

Paul GREENGARD, PhDNobel Laureate

Professor of Molecular and Cellular Neuroscience

Rockfeller University

Eric R. KANDEL, MDNobel Laureate

Professor of physiology and Cellular Biophysics

Columbia University

Paul A. MARKS, MDLaboratory Head of Cell Biology

Memorial Sloan KetteringCancer Center

Bengt SAMUELSSON, MD, PhDNobel Laureate

Professor Karolinska Institutet;Former President Karolinska Institutet; Former Chairman

Nobel Foundation

Jan T. VILCEK, M.D.Professor of MicrobiologyNew York University School

of Medicine

Gerald WEISSMANN, M.D.Professor of Rheumatology

and Director of Biotechnology Study Center

New York University School of Medicine

Elie WIESEL In Memoriam

Honorary Founding President

The Galien Foundation

Peace Nobel Laureate

Boston University

Michael S. BROWN, MDNobel Laureate

Professor of MolecularGenetics and Internal Medicine

UT SouthwesternMedical Center at Dallas

Barry S. COLLER, MDVice President for

Medical Affairsand Physician-in-Chief,Rockefeller University

Walter GILBERT, PhDNobel Laureate

Professor EmeritusHarvard University

Joseph GOLDSTEIN, MDNobel Laureate

Professor of MolecularGenetics and Internal Medicine

UT, SouthwesternMedical Center at Dallas

Joshua LEDERBERG, M.D. Ph.D.Nobel Laureate

Professor Emeritus, Laboratory of Molecular Genetics

and Informatics,Rockefeller University

Richard A. LERNER, M.D.Professor of Immunochemistry,

Chair in ChemistryScripps Research Institute

Richard AXEL, MD

Nobel Laureate

Co-director

The Kavli Institute for Brain

Science. Columbia University Medical Centre

Michael S. BROWN, MD

Nobel Laureate

Professor of Molecular Genetics

and Internal Medicine

UT Southwestern Medical

Center at Dallas

Laurie GLIMCHER, MD

President and CEODana Farber Cancer Institute;Professor of MedicineHarvard Medical School

Joseph GOLDSTEIN, MD

Nobel Laureate

Professor of Molecular Genetics

and Internal Medicine

UT, Southwestern Medical

Center at Dallas

Robert S. LANGER

David H. Koch Institute Professor

MIT

Cato T. LAURENCIN, MD, PhD

University Professor

University of Connecticut

Paul A. MARKS, MD

Laboratory Head of Cell Biology

Memorial Sloan Kettering

Cancer Center

Michael ROSENBLATT, MD

Chief Medical Officer

Flagship Pioneering at Dallas

Bengt SAMUELSSON, MD, PhD

Nobel Laureate

Professor

Karolinska Institutet;

Former President

Karolinska Institutet;

Former Chairman

Nobel Foundation

Marc TESSIER-LAVIGNE, PhD

President

Stanford University

P. Roy VAGELOS, MD

Prix Galien USA

Committee Chairman 2012-2017

Retired Chairman and CEO

Merck & Co., Inc.;

Chairman of the Board

Regeneron Pharmaceuticals, Inc.

5

Susan DESMOND-HELLMANN, MD, MPh

Committee Chair

Chief Executive Officer

Bill & Melinda Gates Foundation

AWARDS COMMITTEE

2018

Our 700 attendees represent the top executive and thought

leadership from academic research, industry, government, the

regulatory community, patient organizations, international

organizations, and the media. Time and again, Forum participants

praise the caliber of the speakers and their fellow attendees,

the quality of the panel discussions and presentations, and

the recognition of industry’s critical role in creating life-saving

innovations.

These events represent peer-to-peer exchange with a public

purpose, and they feature unique opportunities to connect with

a diverse range of people, organizations, and interests, from

professional and scientific groups, academia and governments to

patient associations, non-profit organizations and the media.

Visit the forum webcast to read our 2017 Forum Report on people and substance and to see videos and photos from the event

Topics debated at previous forums include:

> Cancer Immunotherapeutics

> The Brain Initiative

> Personalized Medicine’s Impact on Drug R&D and Patient Care

> Improving efficiency in Drug Development

> What is “Value” and How Can it be Measured and

Demonstrated in Therapeutic Innovations?

> U.S. Health Reform

> A New Agenda for Global Health

> The Future of Digital Health and its Impact on Healthcare

> New Mechanisms for Industry-Academia Collaboration

> The Future of Targeted Drug Delivery

> Microbiota in Human Disease

> Autism - The Next Decade

> Untangling the Web of Neurodegeneration

> Precision Medicine: Delivering on the Promise

> Molecular Scissors: What Can We Expect from Gene Editing?

The Galien Forum, held every autumn at New York’s Alexandria Center for

Life Sciences since 2010, offers a full day of dynamic presentations and

spirited discussions with top scientists and industry researchers who

offer perspectives on the most significant challenges in the global burden

of disease and highlight the latest research and clinical pathways toward

diagnosis, treatment, and cure.

Galien FORUM october 25, 2018 - 7:30AM ALEXANDRIA CENTER FOR LIFE SCIENCE

NEW YORK CITY

6

Margaret A. Hamburg, MDFormer CommissionerU.S. Food and Drug Administration

Sachin H. Jain, MD, MBAChief Medical informationand innovation officer Merck and Co.;Lecturer in Healthcare Policy Harvard Medical School

William N. Hait, MD, PhDGlobal Head, Researchand DevelopmentJanssen Research& Development

Paul Greengard, PhDNobel Laureate Professor of Molecular and Cellular Neuroscience Rockefeller University

Eric R. Kandel, MDNobel LaureateProfessor of Physiologyand Cellular BiophysicsColumbia University;Director Bio-technology Study Center, NYU School of Medicine

Bengt Samuelsson, MD, PhDNobel LaureateFormer PresidentKarolinska InstituteFormer ChairmanNobel Foundation

Michael Rosenblatt, MD Chief Medical Officer Flagship Ventures

Dr Morgan ShengVice PresidentNeuroscience Genentech

George A. Scangos, PhDChief Executive OfficerBiogen Idec

Guido RasiExecutive Director European MedicinesAgency

Laurie Glimcher, MDCEO and PresidentDana Farber Cancer Institute;Professor of MedicineHarvard Medical School

Ezekiel Emanuel, MD, PhDVice Provost for Global Initiatives; Chair,Dept. of Medical Ethicsand Health Policy Levy University Professor Perelman School of Medicine and The Wharton School, University of Pennsylvania

Joseph GoldsteinNobel LaureateProfessor of Molecular Genetics and Internal MedicineUT, Southwestern MedicalCenter at Dallas

Kenneth C. FrazierChaiman, CEO and President,Merck

Dr Alex GorskyChaiman and CEOJohnson & Johnson

Maria C. Freire, PhD President & Executive DirectorFoundation for the National Institutes of Health

Mark McClellan, MD, PhDDirectorDuke-Robert J. Margolis Center for Health Policy;Professor of Business, Medicine, and Health Policy Duke University

Joel S. MarcusChairman, CEO & FounderAlexandria Real Estate Equities /Alexandria Venture Investments; Co-FounderAlexandria Summit

Dr Ira MellmanVice PresidentResearch Genentech

Donald Lloyd-JonesChairman, Departmentof Preventive MedicineNorthwestern University

John LechleiterChairman and CEO Eli Lilly & Cie

Dr Jeffrey LeidenChairman, President and CEOVeritex

Tara Narula, MD, FACCMedical Contributor“CBS This Morning”

Steven H. Stein, MDSenior Vice PresidentUS Clinical Development& Medical AffairsNovartis Oncology US

Marc Tessier-Lavigne PhDPresidentStanford University

Elias ZerhouniPresident, Global R&DSanofi

Krishna Yeshwant, MDGeneral PartnerGoogle Ventures

George Yancopoulos, MD, PhDChief Scientific Officer Regeneron PharmaceuticalsPresident, Regeneron Laboratories

Bert VogelsteinProfessorJohns Hopkins Medical School

P. Roy VagelosM.D., Retired Chairman and CEO, Merck & Co., Inc.Chairman of the Board, Regeneron Pharmaceuticals

Mikael Dolsten, MD, PhDPresident, Worldwide Research and Development Pfizer

Richard Axel, MDNobel Laureate Co-directorKavli Institute for Brain Science, Columbia University Medical Centre

Cori Bargmann PhDRockefeller University

Michael S. BrownNobel LaureateProfessor of Molecular Genetics and Internal MedicineUT Southwestern MedicalCenter at Dallas

Rory CollinsCo-directorUniversity of OxfordClinical Trials Unit

Dr Samantha BuddVice PresidentNeuroscience iMed,AstraZeneca R&D

Michael BloombergFormer Mayor City of New York

AMONG

THE PREVIOUS

GALIEN

FORUM

SPEAKERS

7

“I’d also like to congratulate all thecandidates for the 5th Annual Prix Galien Awards Competition, which honors those

in the pharmaceutical industry who have developed the technical, scientific

and clinical research skills necessary to develop innovative medicines and

devices. Your work is invaluable.“

Margaret A. Hamburg, M.D.

Commissioner of Food and DrugsUS Food and Drug Administration - 2011

“We recognize the importance of the PrixGalien in promoting drug research, and

we salute the excellent work of the Jury.“

Philippe Douste-Blazy French Minister of Foreign Affairs – 2006

“When Olympic rhymes with Galenic: there is a gold medal that can be won

for an extraordinary achievement: this is the Galien Award, the Oscar of

pharmaceutical research.“

Walter SutterSwiss State Advisor, Director

of the Public Economy - 2004

“I applaud Prix Galien for recognizing the pioneering spirit of America

innovation and research.“

John McCain

American Senator - 2008

“Prix Galien recognizes men and women

from the pharmaceutical and biomedical

industries whose contributions of science

have improved and saved countless lives.“

Michael Bloomberg

Mayor of the City of New York - 2010

“The Prix Galien USA recognizes theimportant research necessary to develop innovative medicines and devices that have a life-saving impact on individuals

and families across the globe.“

Kathleen Sebelius

American Secretary of Health and Human Services - 2011

“The Galien Foundation, created to honor and catalyze excellence in scientific innovation, recognizes outstanding

achievement with the prestigious Prix Galien Award.“

Bill De BlasioMayor of the City of New York - 2015

8

A record of leadership in bringing the best of biomedical discovery to the attention of the world…

“

““The Prix Galien is a welcome

initiative to stimulate creative

research and promote excellence.“

Barack Obama

American President - 2008

“I am particularly grateful

to receive this Award.“

Bill Clinton

American President - 2010“The Prix Galien is a prestigious award,

a magnificent occasion to pay recognition to our researchers and

to encourage our industry.“

Jean ChretienCanadian Prime Minister - 1994

“I welcome you to the annual Prix Galien awards for innovative excellence

in biomedical products and health technologies. The awards are among

the highest honors in science and commerce..“

Jimmy Carter

American President - 2017

“It is a pleasure to congratulate all

those who promote the Prix Galien and

pharmaceutical research: they play a vital

role in the fight against disease throughout

the world.“

John Major

British Prime Minister - 1996

“The Prix Galien is the right event, on the

right issue at the right time. I thank the

Galien Foundation for bringing us together

and for recognizing that a healthier world is

a safer world and a more just world.“

BAN Ki-moon

UN Secretary-General - 2010

9

“I know the importance of the Prix Galien

which rewards every year therapeutic

innovations and research works among

the most creative.“

Emmanuel Macron

French President - 2018

“The Prix Galien since 1970 is dedicated

to promoting the research

and development of the medicine

and medicine industries.“

Macky Sall

Senegalese President - 2018

The Prix Galien medal was designed by Albert de Jaeger (1908 – 1992), laureate of

the Premier Grand Prix de Rome architectural prize. De Jaeger designed medals for

prominent figures such as Pope Pius XII (at the Villa Medicis, 1937) and Pope Jean-Paul I,

Presidents Dwight D. Eisenhower and John F. Kennedy, distinguished military leaders

including Marshals Leclerc, Koenig, Montgomery, Marshall and Joukov; the Weizmann

Institute, as well as numerous artists, literary figures and prominent personalities such as Sacha

Guitry, Marcel Proust, Henri de Montherlant, Paul Harris, a number of Nobel Prize laureates, the

Empress of Iran SA Farah Diba, Princess Grace of Monaco, and others…

De Jaeger is also the architect of numerous outstanding monuments in France and throughout the world.

Medalby Albert de JAEGER

The

Merck

Novartis

Roche

Sanofi

GlaxoSmithKline

J&J/Janssen

Pfizer

Bristol-Myers Squibb

Bayer

Amgen

Abbott, Servier

Boehringer Ingelheim

Astra-Zeneca, Inserm, Vertex

Gilead Sciences, Lilly

Biogen, Institut Pasteur, Takeda Actelion, Alexion, Almirall, Teva

AP-HP, Celgene, Chiesi, CTRS, Edwards Life-sciences, Fresenius Biotech, Genzyme, Institut Merieux, Ipsen, Lundbeck, Pierre-Fabre, Procter & Gamble, PTC Thera-peutics, Shire Pharmaceuticals AAZ, AbbVie, Abbott/AbbVie, Albana Pharma, Army Health Department - France, Astellas, Baxter, Biocodex, Boston Scientific, Centre of Polymer and Carbon Materi-als of the Polish Academy of Sciences, Chugaî, Engel-hardt Institute of Molecular Biology, EOS Imaging, Ferrer, Genethon, Genentech, Generium, Guerbet, Institut Santa Creu, Intercept Pharmaceuticals, Insightec, Intermunde, Ionis Pharmaceuticals, Leo, LFB, Menarini, Norgine GmbH, Orphan, Otzuka, PharmaPharm, Roche/Genen-tech, Swedish Orphan International, T2 Biosystems, Uriach, Viron Therapeutics,

B Y N U M B E R O F M E D A L S

Hall of famePRIX GALIEN

Around the globe since 1970

51

45

6

42

5

37

4

35

3

32

2

1

28

23

17

16

Updated December 2017

11

8

10

1 1

Our annual gala awards dinner is a creative

recognition of the productive and positive power

of partnerships that drive progress in medical

science. It is peer exchange with a public purpose

- with a diverse range of opportunities for contact

with a range of interests, from professional and

scientific groups, academia and governments

to patient associations, other non-profit

organizations and the media.

october 25, 20186:30 PM

Galien AWARDS CEREMONY

AMERICAN MUSEUM OF NATURAL HISTORY

NEW YORK CITY

WHAT PREVIOUS PRIX GALIEN WINNERS HAVE SAID UPON RECEIVING THE HONOUR

“Merck’s mission is to

translate science into

medically important

products that positively

impact humanity, so it is

natural for us to support the Prix

Galien, since it supports exactly that.”

Kenneth C. Frazier

Chaiman, CEO and President

Merck

2018

“Our 2016 Prix Galien award

highlights not only the

breakthrough science behind

Cologuard, but also the

unrivaled team that worked to

develop and bring to market an innovation

with the potential to make a significant

impact in eradicating colorectal cancer. We

are humbled and thankful to be counted

among the companies honored by the

Galien Foundation.”

Graham Lidgard, PhD

Chief Science Officer

Exact Sciences

“Our goal — to combine the

best science with the most

efficient drug development

plan and deliver

transformational medicines to

patients in need — is completely aligned

with the Galien Foundation mission to

promote innovations that improve the

human condition.”

Mace L. Rothenberg,

M.D. Chief Development Officer, Oncology -

Pfizer Global Product Development

“The Galien Foundation

brings together the top

scientists in the world.

You have Nobel Laureates

across the spectrum of

scientific disciplines meeting and

talking with members of the pharmaceutical

industry to see what’s going on at the

cutting edge, because ultimately that’s

going to benefit patients.”

William Hait, MD, PhD

Global Head, Research & Development

Janssen, Pharmaceutical Companies of

Johnson & Johnson

“Our 2016 Prix Galien USA

awards [for Cosentyx and

Gleevec] … represent years

of hard work by our scientists.

These wins underscore our

commitment to addressing the

unmet medical needs of patients through

science-based innovation.”

Joseph Jimenez

CEO

Novartis

The committee follows a century-old example set in Sweden.

The Prix Galien rewards excellence and novelty, and awards special honors to

those who have served humanity at large. Presented at the Ceremony, the Pro

Bono Humanum Award recognizes exemplary and innovative efforts in improving

the human condition. This special award was presented by the late and beloved

Elie Wiesel, in presence of the Prix Galien USA Committee.

2011Pr. Paul Farmer in recognition of his heroic efforts to do “whatever it takes” to improve the lives and health of patients in destitute communities around the world through the Partners in Health initiative which he co-founded with Tom White.

2010Bill Clinton and Philippe Douste-Blazy, in recognition of their outstanding achievements in providing treatment for underserved populations through the William J. Clinton Foundation HIV / AIDS Initiative and the multilateral organization, UNITAID.

2009Harvard Professor Barry Bloom for bringing the fruits of basic biological science to those who are most needy. Columbia University Earth Institute Director Jeffrey Sachs for bringing the fruits of scholarly economics to bear our problems that have plagued the world for millennia.

2008Sheldon Segal and the Population Council for their global efforts in support of reproductive health and family planning.

2007Former Merck CEO Roy Vagelos, for the River Blindness Program and his historic decision to donate the drug Mectizan® to more than 530 million people in 34 countries to treat and prevent river blindness: “as much as necessary for as long as necessary.”

2017President Jimmy Carter & The Carter CenterIn recognition of his role as the nation’s 39th President in expanding access to childhood immunizations and, for the first time, adding social progress and human rights as a foundational principle of US foreign policy. The Prix Galien USA Committee also commends his unmatched record in public health provision after leaving office, launching the Carter Center in 1982 and subsequently positioning it as a leading global donor on programs to control and eradicate six major communicable diseases prevalent in developing

countries. This includes the eradication of the Guinea worm disease as well as the MECTIZAN initiative to control the scourge of river blindness in Africa and Latin America, which today serves as a precedent for productive public-private partnerships. The Committee points as well to his selection as recipient of the Nobel Peace Prize in 2002, in which the Swedish Academy noted his decades of effort to promote individual freedoms and economic and social development for all. These are now recognized around the world as important drivers of individual health status.

2016Paula S. Apsell

In recognition of her early and

continuing leadership in Making the

complexities of science, engineering

and medical research accessible to a

mass audience. Through innovative

broadcast and digital programming

of the highest journalistic

standard, her work has educated,

entertained and enlightened

successive generations of viewers

on the mysteries that underlie our

understanding of the natural world.

And by turning great science into

a good story - a human story - Ms.

Apsell shows that scientific literacy

is society’s essential line of defense

against the destructive forces of fear,

ignorance and blight.

2015Pr. Mary-Claire King

In recognition of your

work in transforming the

application of human

genetics to medicine through

identification of

the first gene, BRCA1,

responsible for inherited

susceptibility to breast

cancer. You also

demonstrated that the

genomes of humans and

chimpanzees are 99%

identical, and you pioneered

the application of genetic

sequencing in forensics to

identify victims of human

rights abuse.

2014Bernard Kouchner, M.D.

In recognition of his role in

the creation, from amongst

French doctors, this group of

“Doctors Without Borders”

who have lent the modern

field of humanitarian

medicine both legitimacy

and worldwide acclaim and

for his fieldwork that has

nurtured and developed,

not only among public

opinion but also within

various governments, the

notion of the universality

of humanitarian action and

the concept of the Non-

Governmental Organization.

2013Dr. Anthony Fauci

for his paramount

contributions to basic and

clinical research on the

pathogenesis and treatment

of immunemediated and

infectious diseases.

He currently serves as

Director of the NIAID and

chief of the NIAID Laboratory

of Immunoregulation in

Bethesda, Maryland.

2012Dr. Francis S. Collins.

Dr. Collins, Director of the

National Institutes of Health

(N.I.H)

In recognition of his

contribution to the ethical

implications of scientific

research

12

The Prix Galien USA Committee, a group of highly accomplished individuals from the scientific and research communities,

will judge which among the candidates, independent of any category, is the Best Pharmaceutical Agent (i.e. small molecule),

is the Best Biotechnology Product and which is the Best Medical Technology approved by the FDA in the past ten years. As

few as one or as many as three prizes may be awarded in each of these categories, and from time to time the committee

may decide on awards hors prix. The prizes are awarded for products and agents that improve the human condition.

An UNRIVALED REPUTATION FOR INTELLECTUAL RIGOR AND INTEGRITY…

Elie Wiesel, Peace Nobel Laureate;

BAN Ki-moon, General Secretary, United Nations;

Bill Clinton & Philippe Douste-Blazy,

2010 Prix Galien Pro Bono Humanum Award Laureate

Born in 131AD, Galen (Galien in French) is

considered the father of modern medicine

and pharmacology.As an anatomist,

physiologist, clinician and researcher,

his work formed the basis of a school

of thought known as “Galenism”, which

dominated medicine until the Renaissance.

In fact, Galen’s works were used as primary

medical reference for nearly two centuries.

Raised in Pergamos, he studied in Smyrna,

Corinth, and Alexandria, the three centers

of medical excellence in the ancient world.

Legend has it that Galen was visited

by Aesclapius in a dream and that this

inspired the direction of his life. When he

was 17, Galen worked as a physician to

the gladiatorial school. At the age of 37,

Marcus Aurelius summoned him to Rome,

where he grew in reputation and stature

as a healer, teacher, researcher and writer.

His ideas on the functioning of the human

body were so well received that he became

the personal doctor of young Commodus,

the heir to the Emperor. He died in 201AD.

During his long and eminent career, Galen

completed over five hundred learned works

addressing anatomy, physiology, pathology,

medical theory and practice, and many

forms of therapy. He traveled throughout the

world, studying local plants and remedies,

eventually describing 473 original drugs and

many substances of mineral and vegetable

origin. Importantly, Galen was the first to

codify the art of preparing active drugs

using multiple ingredients. Galen’s faculties

of observation, logic and deduction made

him the true successor of Hippocrates,

and his declaration that the primary aim of

medicine was patient care formed the very

cornerstone of modern pharmacy.To quote

Jean-Pierre Changeux, “Galen first showed

that our mind was in the brain, not in our

hearts.” It can be said that this was the

beginning of experimental medicine.

Who was Galien?

13

The mission of The Prix Galien-MedStartUp program is to foster

private-sector collaborations to treat and cure medical conditions

that pose a threat to public health worldwide and promotes

foster innovative research partnerships among major integrated

pharmaceutical companies, biotech firms, and medical device

manufacturers, producers of vaccines, academic research institutes,

and health care organizations, including e-health vendors.

This unique initiative, which takes place in

the same venue and at the same time as the

Galien Forum, was built on several years of

cooperation between the Galien Foundation and

Business France with three core goals:

Strengthen commercial partnerships

that bridge the traditional silos between

government, industry and academia;

Defray the growing complexity and cost

burden of medicines R&D; and

Promote cross-border trade, jobs, and

economic growth.

A focal point of the program is the active

participation of the most innovative start-up

companies who are seeking US partners to

share research and support global commercial

development of promising lead technologies.

Each year the Jury nominates candidates

for four awards in the following categories:

Best Collaboration/Partnership with an

Academic institution in a Breakthrough

Therapy

Best Innovative Clinical Trial Design to achieve

a Faster and Better Therapeutic Outcome

Best Use of a Patient-Centered Health

Engagement Technology

Best Collaboration/Partnership in a

Breakthrough Therapy or Diagnosis

geared to Developing Countries.

14

THE JURY

JOIN US ON : http://medstartup.galienfoundation.org +

François MAISONROUGESenior Managing Director,Evercore Partners

Paul STOFFELSChief Scientific Officer, Johnson and Johnson

Elias ZERHOUNIGlobal R&D President, Sanofi

!

!

!

Roch DOLIVEUXHonorary CEO, UCB

Mikael DOLSTENGlobal R&D President, Pfizer

Jean-Pierre GARNIERFormer CEO, GSK

Franz HUMERFormer CEO, Roche

!

!

!

!

!

Chairman:

Bernard POUSSOT

Director, Roche Holding, Former Chairman & CEO, WYETH

15

2017Best Pharmaceutical Product: Venclexta™, AbbVie & Genentech (a Member of the Roche Group)

Best Biotechnology Product: SPINRAZA®, Biogen & Ionis Pharmaceuticals

Best Medical Technology: Exablate Neuro, INSIGHTEC

Pro Bono Humanum Award:Former President Jimmy Carter

2016Best Pharmaceutical Agent: Ibrance®, Pfizer, Inc.

Best Biotechnology Product: Cosentyx®, Novartis Pharma.

Best Medical Technology: Cologuard®, Exact Sciences

Discovery of the Decade winners:

Best Pharmaceutical Agent: Gleevec®, Novartis Pharma.

Best Biotechnology Product: Yervoy®, Bristol-Myers Squibb

Best Medical Technology: Sapien 3TM, Edwards Lifesciences Corpo.

Pro Bono Humanum Award: Paula S. Apsell

2015Best Pharmaceutical Agent: IMBRUVICA®, Janssen Biotech, Inc. & Pharmacyclics LLC, an AbbVie Company

Best Biotechnology Product: OPDIVO®, Bristol-Myers Squibb KEYTRUDA®, Merck & Co., Inc.

Best Medical Technology: T2Candida Panel, T2 Biosystems, Inc.

Pro Bono Humanum Award:Pr. Mary-Claire King

2014Best Pharmaceutical Agent: Sovaldi® - Gilead Sciences

Best Biotechnology Product: HEMACORD® - The New York Blood Center’s Howard P. Milstein Cord Blood Center

Best Medical Technology: Trevo ProVue® - Stryker

Pro Bono Humanum Award:Dr. Bernard Kouchner

2013Best Pharmaceutical Agents:Zelboraf® - Genentech

Best Biotechnology Product:Zostavax® - Merck

Best Medical Technology product:S-ICD® System - Boston Scientific

Pro Bono Humanum Award:Dr. Anthony S. Fauci

2012Best Pharmaceutical Agents:Victrelis® - Merck; Incivek® - Vertex

Best Biotechnology Product:Yervoy® - Bristol-Myers Squibb

Best Medical Technology product: Sapien® - Edwards Lifesciences’Melody® - Medtronic

Pro Bono Humanum Award:Dr. Francis S. Collins

2011Best Pharmaceutical Agent:Prevnar13® - Pfizer

Best Biotechnology Product:Stelara® - Janssen Prolia and XGEVA® - Amgen

Pro Bono Humanum Award:Paul Farmer

2010Best Pharmaceutical Agent:Coartem® - Novartis

Best Biotechnology Product:RotaTeq® - Merck & Co.

Best Medical Technology:xTAG® - Luminex Corporation

Pro Bono Humanum Award:Bill Clinton and Philippe Douste-Blazy

2009Best Pharmaceutical Agent:Gleevec® - Novartis

Best Biotechnology Product:Nplate® - Amgen; Promacta® - GSK

Best Medical Technology:Cellsearch® - Veridex (J&J)

Pro Bono Humanum Award:Jeffrey Sachs and Barry Bloom

2008Best Pharmaceutical Agent:Isentress® - Merck; Selzentry® - Pfizer

Best Biotechnology Product:Soliris® - Alexion; Infuse® - Wyeth

Special therapeutic development:Revlimid® - Celgene

Pro Bono Humanum Award:

Sheldon Segal

2007Best Pharmaceutical Agent:Januvia® - Merck; Chantix® - Pfizer

Best Biotechnology Product:Humira® - Abbott; Gardasil® - Merck

Pro Bono Humanum Award:Dr. Roy Vagelos

And in 2018, the winners are…PRIX GALIEN USA WINNERS

The Galien Foundation

99 John Street , Suite 2502.

New York, New York 10038

212-685-1592

and the winner is…

Actors win Oscars. . .

Innovators win Prix Galien USA

The Galien Foundation

99 John Street, Suite 2502

New York, NY 10038

Tel: 212-685-1592

Prevnar13® / Prolia and XGEVA® / Stelara®

Coartem® / Rotateq® / xTAG®

HemacordTM / Trevo®ProVueTM

Sovaldi®

S-ICD® SystemZelboraf® / Zostavax®

Imbruvica®/ Keytruda®/ Opdivo® / T2Candida Panel

Cologuard® / Cosentyx® Ibrance®

2016 2016

2015 2015

2014 2014

2013 2013

2011 2011

2010 2010

Cellsearch® / Gleevec® / Nplate® / Promacta®2009 2009

Infuse® / Isentress® / Revlimid®/ Selzentry® / Soliris®2008 2008

Chantix® / Gardasil® / Humira® / Januvia® 2007 2007

www.galienfoundation.org

OCTOBER 25, 2018

AMERICAN MUSEUM OF NATURAL HISTORY

Exablate Neuro®

Spinraza® / VenclextaTM 2017 2017

Incivek® / Melody® / Sapien®

Victrelis® / Yervoy®2012 2012